4 articles
State-owned PICC Property and Casualty signed China's first commercial insurance policy covering invasive brain-computer interface surgery on Wednesday 12 August 2026. Counterparty is the Second Affiliated Hospital of Zhejiang University School of Medicine. Zhejiang Provincial Government Office released a same-day industry-policy package. Hong Kong and Shenzhen BCI-tagged stocks rallied.
Shanghai Active Technology, founded February 2026, closed a RMB 330 million angel round announced on 3 August 2026. Gasgoo and 36Kr describe the raise as the largest single angel round in the Chinese BCI sector to date, though the lead investor was not disclosed. The company is building a full-link invasive BCI with three product lines including a 1024-channel motor system called Tianshu, which has obtained a type inspection report and is preparing to launch clinical trials.
In one month, four separate Chinese brain-computer interface programmes each produced a public result. Neuracle wrote the world's first commercial prescription for an invasive BCI at Huashan Hospital on 13 July. NeuroXess ran a two-patient cross-city Chinese chess demonstration between Shanghai and Nanchang. StairMed's investigational trial put three quadriplegic patients into paid remote work. And at the World AI Conference in Shanghai, a paralysed fine-arts graduate from Shenzhen demoed a mind-controlled wheelchair he had built himself with LLM-assisted DIY.
China's National Medical Products Administration issued Announcement No. 24 (2026) on 29 June 2026, releasing final Guiding Principles for the Classification and Definition of Brain-Computer Interface Medical Device Products plus a companion Generic Naming Guidelines. Every invasive BCI is Class III. Non-invasive BCIs are Class III by default. Non-invasive stroke-motor rehabilitation devices are Class II only if they do not incorporate artificial intelligence.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.